Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries

Sang Gune K. Yoo, Grace S. Chung, Silver K. Bahendeka, Abla M. Sibai, Albertino Damasceno, Farshad Farzadfar, Peter Rohloff, Corine Houehanou, Bolormaa Norov, Khem B. Karki, Mohammadreza Azangou-Khyavy, Maja E. Marcus, Krishna K. Aryal, Luisa C.C. Brant, Michaela Theilmann, Renata Cífková, Nuno Lunet, Mongal S. Gurung, Joseph Kibachio Mwangi, Joao MartinsRosa Haghshenas, Lela Sturua, Sebastian Vollmer, Till Bärnighausen, Rifat Atun, Jeremy B. Sussman, Kavita Singh, Sahar Saeedi Moghaddam, David Guwatudde, Pascal Geldsetzer, Jennifer Manne-Goehler, Mark D. Huffman, Justine I. Davies, David Flood

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Importance: Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. Objective: To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. Design, Setting, and Participants: Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. Exposures: Countries' per capita income levels and world region; individuals' socioeconomic demographics. Main Outcomes and Measures: Self-reported use of aspirin for secondary prevention of CVD. Results: The overall pooled sample included 124505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10589 individuals had a self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. Conclusion and Relevance: Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy..

Original languageEnglish
Pages (from-to)715-724
Number of pages10
JournalJAMA
Volume330
Issue number8
DOIs
StatePublished - Aug 22 2023

Fingerprint

Dive into the research topics of 'Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries'. Together they form a unique fingerprint.

Cite this